Shares of Rapport Therapeutics, Inc. (RAPP) surged 5.20% during intraday trading on Wednesday, reflecting significant positive momentum.
The sharp rise appears driven by bullish analyst sentiment, including Wells Fargo raising its price target on the stock from $43 to $46, alongside other positive insights from analysts covering the healthcare sector.